This analysis shows intravenous vancomycin improves therapeutic efficacy in peritoneal dialysis patients, suggesting effective treatment options.
In settings where intraperitoneal vancomycin is unavailable or off‐label (e.g., Japan), intravenous vancomycin can be a viable treatment option for peritoneal dialysis‐associated peritonitis. Due to limited pharmacokinetic data regarding intravenous dosing, pragmatic strategies involving more frequent therapeutic drug monitoring—measuring both serum levels for systemic safety and dialysate levels for intraperitoneal antimicrobial exposure—can help ensure therapeutic efficacy while maintaining patient safety.
No takes yet. Share an insight, caveat, or question.
Yonezawa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: